Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

BACKGROUND: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder. METHODS: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients with major depressive disor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Neuropsychopharmacol
Main Authors: Connor, Kathryn M, Ceesay, Paulette, Hutzelmann, Jill, Snavely, Duane, Krystal, Andrew D, Trivedi, Madhukar H, Thase, Michael, Lines, Christopher, Herring, W Joseph, Michelson, David
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570043/
https://ncbi.nlm.nih.gov/pubmed/28582570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyx033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados